Tolerance Bio

Executive Summary

Tolerance Bio is a private biotechnology company headquartered in San Diego, California, founded in 2019 with a mission to increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. The thymus is critical for educating T cells to distinguish self from non-self, and its age-related decline contributes to a wide range of immune-mediated diseases including cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies. Tolerance Bio aims to develop therapies that rejuvenate thymic function and re-establish immune balance, addressing significant unmet medical needs across multiple large therapeutic areas. The company leverages deep expertise in thymus biology and regenerative medicine to create novel cell and gene therapy approaches.

Upcoming Catalysts (preview)

• Q2 2026Series A Financing Announcement65% success
• Q4 2026IND-enabling Preclinical Data Release70% success
• Q1 2027First Investigational New Drug (IND) Submission55% success